Health New Zealand has handed out more than 2300 peptide injecting kits through the Needle Exchange Programme in the six weeks since 15 September, as pharmacies and exchange outlets deal with a wave of people injecting unapproved peptides bought online for weight loss, muscle building, anti-ageing and tanning.
The kits have gone to around 190 pharmacies and regional needle exchange providers, according to a Health New Zealand media release issued on Wednesday. Each kit contains syringes, needles, a returns container and an information leaflet, and pharmacies order them through the same process they use for other exchange equipment. Used gear goes back in the container to the nearest pharmacy or exchange outlet.
Deborah Woodley, Health New Zealand’s director of maternity, child, youth and prevention, said the uptake “reflects the significant demand for equipment tailored to peptide injecting”. She added that “access to sterile injecting equipment does not imply endorsement of unapproved peptide use by Health NZ” and that the agency’s focus was on “reducing preventable harm and ensuring people have access to accurate information”.
Bronwyn Petrie, Health New Zealand’s group manager of population health, told RNZ’s Morning Report on Thursday that nobody yet knows how big the market is. “I don’t think we know the size and scale of the unapproved peptides in New Zealand, but what we do know is that internationally and here in New Zealand, there has been a huge spike in people injecting peptides,” she said.
“But critically, I really want to point out that this shouldn’t be seen as an endorsement of unapproved peptides. It’s about supporting our providers, responding to the demand, meeting people where they are, and ultimately preventing potential harm.”
The Needle Exchange Programme was set up in the late 1980s so that people who inject drugs could get clean equipment, and it is funded by Health New Zealand. It works on confidentiality, so nobody records who walks in. Petrie said the new customers are not the people the service was built for. “But anecdotally we have heard you know, whether it be a gym user or whether it be a mother coming in wanting something for their child, it’s a really wide range of people and I think that’s what makes it even more challenging in many ways,” she said. She did not know the details of the mother’s case, but said it “could be associated with growth or muscle healing or a whole range of different things”.
The scale of the shift shows up in the programme’s own sales figures. A Ministry of Health briefing to Mental Health Minister Matt Doocey, released to Newstalk ZB under the Official Information Act earlier this month, showed 26,731 one-millilitre insulin needles were bought through the programme’s online shop between January and June 2025. In the same six months of 2026 the figure was 141,523, more than five times as many. Some exchange services have had to ration supplies, in some cases limiting clients to six to ten syringes.
The briefing said needle exchanges were reporting “around a doubling in clients and almost ten-fold increase in demand for peptide specific injecting equipment through the online store in the past year”. Officials warned that “this is putting pressure on equipment supply and disrupting the services for traditional, high-risk intravenous [IV] clients”. Woodley told Newstalk ZB at the time that some front-line sites had seen an increase of up to 30 per cent in clients seeking peptide equipment.
Peptides are short chains of amino acids. “Peptides are small substances made naturally in the body that act as signals, helping to regulate things like growth, healing, hormones and our metabolism,” Petrie said. Some are legitimate prescription medicines, including the weight loss and diabetes drugs Ozempic, Wegovy and Mounjaro. The problem is the grey market that has grown around them, where products such as retatrutide, BPC-157 and TB-500 are sold on overseas websites “for research purposes only” and promoted by influencers on social media as shortcuts to fat loss, recovery and younger skin.
Until last summer, many of those products fell through a gap in the law. In a June 2025 submission to the Medicines Classification Committee, Medsafe reported that 56 parcels containing peptides or similar drugs had been intercepted at the border in just seven weeks that autumn. Because most of the peptides were not scheduled as prescription medicines, Medsafe had no power under the Medicines Act 1981 to seize them, and the parcels were released to the buyer with a warning letter. The committee deferred a decision in July 2025 while it sought more information. A gazette notice on 19 December 2025 then classified ten groups of peptides as prescription medicines, including BPC-157 and its analogues, thymic peptide hormones, kisspeptins and myostatin modulators, along with retatrutide and several individually named compounds.
That change gave Medsafe the power to stop parcels at the border. In July the regulator told Newstalk ZB it had intercepted more than 370 parcels containing peptides and similar drugs in 2025, up from 15 in 2022, and more than 200 in the first four months of 2026 alone. It said it had contacted 22 New Zealand websites selling peptides and all had been taken down.
Medsafe’s consumer advisory of 21 May 2026 set out the case against the products in plain terms. “There is a very real risk that these products may be of poor quality, not contain the substance claimed on the label (if they are labelled), contain other harmful substance not on the label or not be sterile (and so may contain substantial quantities of germs or mould),” it said. “Even if these products actually contain the advertised ingredient, there is no good scientific evidence that they work as advertised or that they are safe. Neither is there any evidence that these products are sterile, and because they are injected, it means there is a high risk of a life-threatening infection from using them.”
Petrie said that warning was “pretty clear” and Health New Zealand’s job was to make sure providers had the information and the packs to hand out. “And really our key messages are if you are injecting peptides, you know, speak to a health professional, but also please use sterile equipment, never share needles and dispose of it safely,” she said. Health New Zealand has released a podcast on peptides, is developing educational resources for pharmacies and clients, and is working with the Ministry of Health on a wider response.
Professor Chris Wilkins, who leads the drug research team at Massey University’s SHORE and Whariki Research Centre, told Newstalk ZB the core problem was manufacturing without any regulatory oversight. “People don’t know what they’re actually getting. They can’t rely on the advertising that might be online or the text message they get, and then they’re taking the further step of injecting these things into themselves,” he said. He added that the trend overlapped with wider worries about young people, body image and social media, and “might be a lot larger than we think”.
For now, the kits are the most visible part of the response. Nearly 400 a week have gone out since mid-September, through a service designed for a very different group of people, and Health New Zealand says demand is still growing.
Have you seen peptides promoted in your social media feed, or noticed the change at your local pharmacy? Tell us what you think in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job π


Leave a Reply